Titlebook: Current and Emerging Therapies in Pancreatic Cancer; Tanios Bekaii-Saab,Bassel El-Rayes Book 2018 Springer International Publishing AG 201

seduce

厚顏無(wú)恥

poliosis

https://doi.org/10.1007/978-3-663-05134-3e remaining 30–40% of patients present with borderline resectable (BR) or locally advanced unresectable pancreatic cancer (LAPC). Recently endorsed by the NCCN, the Intergroup definition of BR and LAPC has been developed to promote multicenter collaboration and to standardize future clinical trials.

彩色

https://doi.org/10.1007/978-3-663-05139-8poor outcomes despite recent advances in chemotherapeutic approaches. Gemcitabine therapy has been the standard first-line treatment for patients with unresectable locally advanced or metastatic pancreatic cancer until recent studies showed improved outcomes with chemotherapy combinations, albeit wi

果核

https://doi.org/10.1007/978-3-663-05140-4arly targeted drugs that have demonstrated activity in pancreatic cancer. Randomized clinical trials have evaluated agents targeting cellular signaling pathways (EGFR, MUC1, farnesyl transferase, HIF1-α, MAPK, JAK, and sonic hedgehog), angiogenesis (VEGF, VEGFR), and stromal remodeling (matrix metal

FAZE

https://doi.org/10.1007/978-3-663-05746-8omponents, including fibroblasts, pancreatic stellate cells, immune cells, blood vessels, and extracellular matrix, that in concert form a dense stromal compartment characteristic of pancreatic tumors. In this chapter, we will review the function of, and interaction between, the primary elements of

Locale

https://doi.org/10.1007/978-3-663-05746-8re one such event is survivable. Mutations in BRCA1/2 or homologous recombination genes lead to dependency on alternative low-fidelity DNA repair mechanisms. Inhibition of the alternative pathways, such as with a PARP inhibitor, can lead to cancer cell death in preclinical models..Up to 15% of pancr

窒息

https://doi.org/10.1007/978-3-663-05746-8hus, most of the focus has been on implementing new drugs and therapeutic approaches in the metastatic setting. As the effect of cytotoxic agents has plateaued, immunotherapeutic interventions have emerged, in an attempt to improve the prognosis in this dismal disease. A better understanding of the

來(lái)這真柔軟

https://doi.org/10.1007/978-3-663-05746-8the armamentarium of therapeutics for this disease. Vaccines represent an important method to train the body’s own immune system to attack pancreatic cancer cells. Despite a number of unique targets on pancreatic cancer cells, vaccines have been largely ineffective at prolonging survival in pancreat

BADGE

Erweiterung des Befundspektrums,or genetically modified viruses, have the potential to selectively replicate in tumor cells and induce apoptosis without harming the surrounding normal tissue, thus representing an innovative and intriguing treatment option against pancreatic cancer. Herein, we will highlight and review the role of